REDWOOD CITY, Calif., Dec. 29, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. ARMO BioSciences, Inc. has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol "ARMO."
Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the proposed offering. Robert W. Baird & Co. Incorporated is acting as co-manager.
The proposed offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at [email protected]; Leerink Partners LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525 ext. 6132 or by email at [email protected]; or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at 800-414-3627, or by email at [email protected].
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Advertisement
Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the proposed offering. Robert W. Baird & Co. Incorporated is acting as co-manager.
Advertisement
The proposed offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at [email protected]; Leerink Partners LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525 ext. 6132 or by email at [email protected]; or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at 800-414-3627, or by email at [email protected].
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View original content:http://www.prnewswire.com/news-releases/armo-biosciences-files-registration-statement-for-proposed-initial-public-offering-300576199.html
SOURCE ARMO BioSciences, Inc.
